Suzanne Edavettal, Pilar Cejudo-Martin, Bidisha Dasgupta, Danlin Yang, Matthew D Buschman, Derrick Domingo, Kristof Van Kolen, Pharavee Jaiprasat, Renata Gordon, Keith Schutsky, Brian Geist, Natalie Taylor, Camille Helene Soubrane, Elisabeth Van Der Helm, Ann LaCombe, Zemeda Ainekulu, Eilyn Lacy, Jason Aligo, Jason Ho, Yingbo He, Peter F Lebowitz, James T Patterson, Justin M Scheer, Sanjaya Singh
BACKGROUND: The near impermeability of the blood-brain barrier (BBB) and the unique neuroimmune environment of the CNS prevents the effective use of antibodies in neurological diseases. Delivery of biotherapeutics to the brain can be enabled through receptor-mediated transcytosis via proteins such as the transferrin receptor, although limitations such as the ability to use Fc-mediated effector function to clear pathogenic targets can introduce safety liabilities. Hence, novel delivery approaches with alternative clearance mechanisms are warranted...
October 12, 2022: Med